Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.01 - $4.17 $168,831 - $350,263
83,996 Added 7.23%
1,245,668 $3.44 Million
Q4 2022

Feb 14, 2023

BUY
$1.78 - $3.64 $90,614 - $185,301
50,907 Added 4.58%
1,161,672 $2.3 Million
Q3 2022

Nov 14, 2022

BUY
$2.89 - $5.32 $37,454 - $68,947
12,960 Added 1.18%
1,110,765 $3.3 Million
Q2 2022

Aug 15, 2022

BUY
$3.27 - $8.76 $458,221 - $1.23 Million
140,129 Added 14.63%
1,097,805 $3.79 Million
Q1 2022

May 16, 2022

BUY
$7.56 - $14.3 $1.53 Million - $2.9 Million
202,592 Added 26.83%
957,676 $7.84 Million
Q4 2021

Feb 14, 2022

BUY
$12.24 - $21.25 $5.14 Million - $8.93 Million
420,258 Added 125.52%
755,084 $10.8 Million
Q3 2021

Nov 15, 2021

SELL
$16.69 - $26.05 $1.67 Million - $2.61 Million
-100,000 Reduced 23.0%
334,826 $6.44 Million
Q2 2021

Aug 16, 2021

BUY
$18.15 - $27.75 $2.72 Million - $4.16 Million
150,000 Added 52.66%
434,826 $11 Million
Q1 2021

May 17, 2021

SELL
$20.71 - $51.02 $2.05 Million - $5.04 Million
-98,854 Reduced 25.76%
284,826 $7.01 Million
Q4 2020

Feb 16, 2021

SELL
$21.84 - $44.0 $16.2 Million - $32.6 Million
-740,719 Reduced 65.88%
383,680 $14 Million
Q3 2020

Nov 16, 2020

BUY
$13.63 - $24.12 $12.7 Million - $22.5 Million
933,150 Added 487.92%
1,124,399 $24.4 Million
Q2 2020

Aug 14, 2020

SELL
$7.65 - $14.11 $205,685 - $379,375
-26,887 Reduced 12.33%
191,249 $2.48 Million
Q1 2020

May 15, 2020

SELL
$4.75 - $12.41 $888,497 - $2.32 Million
-187,052 Reduced 46.16%
218,136 $1.76 Million
Q4 2019

Feb 14, 2020

BUY
$8.73 - $12.95 $3.1 Million - $4.6 Million
355,093 Added 708.84%
405,188 $4.42 Million
Q2 2019

Aug 14, 2019

BUY
$27.0 - $30.25 $1.35 Million - $1.52 Million
50,095 New
50,095 $0

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $171M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.